Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

760 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Chi G, Gibson CM, Kalayci A, Cohen AT, Hernandez AF, Hull RD, Kahe F, Jafarizade M, Sharfaei S, Liu Y, Harrington RA, Goldhaber SZ. Chi G, et al. Among authors: harrington ra. Intensive Care Med. 2019 Apr;45(4):477-487. doi: 10.1007/s00134-019-05565-6. Epub 2019 Feb 18. Intensive Care Med. 2019. PMID: 30778649 Clinical Trial.
Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture.
Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Gibson CM, et al. Among authors: harrington ra. J Thromb Thrombolysis. 2003 Jun;15(3):189-96. doi: 10.1023/B:THRO.0000011374.60110.bc. J Thromb Thrombolysis. 2003. PMID: 14739628
Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction.
Roe MT, Green CL, Giugliano RP, Gibson CM, Baran K, Greenberg M, Palmeri ST, Crater S, Trollinger K, Hannan K, Harrington RA, Krucoff MW; INTEGRITI Investigators. Roe MT, et al. Among authors: harrington ra. J Am Coll Cardiol. 2004 Feb 18;43(4):549-56. doi: 10.1016/j.jacc.2003.09.039. J Am Coll Cardiol. 2004. PMID: 14975462 Free article. Clinical Trial.
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.
Gibson CM, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E; TIMI Study Group. Gibson CM, et al. Among authors: harrington ra. J Am Coll Cardiol. 2004 Apr 7;43(7):1170-6. doi: 10.1016/j.jacc.2003.11.035. J Am Coll Cardiol. 2004. PMID: 15063425 Free article.
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.
Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA, Cholera S, Krishnan R, Califf RM, Braunwald E; INTEGRITI Study Group. Gibson CM, et al. Among authors: harrington ra. Circulation. 2004 Aug 10;110(6):679-84. doi: 10.1161/01.CIR.0000137912.11655.F6. Epub 2004 Jul 19. Circulation. 2004. PMID: 15262838 Clinical Trial.
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E; EARLY ACS Steering Committee. Giugliano RP, et al. Among authors: harrington ra. Am Heart J. 2005 Jun;149(6):994-1002. doi: 10.1016/j.ahj.2005.03.029. Am Heart J. 2005. PMID: 15976780
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
Alexander JH, Ferguson TB Jr, Joseph DM, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. Among authors: harrington ra. Am Heart J. 2005 Oct;150(4):643-9. doi: 10.1016/j.ahj.2005.05.021. Am Heart J. 2005. PMID: 16209958
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative.
Patel MR, Chen AY, Peterson ED, Newby LK, Pollack CV Jr, Brindis RG, Gibson CM, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, Ohman EM, Harrington RA, Roe MT. Patel MR, et al. Among authors: harrington ra. Am Heart J. 2006 Oct;152(4):641-7. doi: 10.1016/j.ahj.2006.02.035. Am Heart J. 2006. PMID: 16996828
760 results